Your browser is no longer supported. Please, upgrade your browser.
NEW! We've added Bitcoin charts to our Forex section. ×
Johnson & Johnson
IndexDJIA S&P500 P/E17.91 EPS (ttm)5.59 Insider Own0.01% Shs Outstand2.77B Perf Week-2.23%
Market Cap277.69B Forward P/E15.61 EPS next Y6.41 Insider Trans-52.18% Shs Float2.77B Perf Month0.48%
Income15.92B PEG3.49 EPS next Q1.69 Inst Own67.40% Short Float1.09% Perf Quarter-1.60%
Sales73.59B P/S3.77 EPS this Y18.50% Inst Trans-0.46% Short Ratio3.86 Perf Half Y-4.80%
Book/sh24.39 P/B4.11 EPS next Y4.46% ROA15.70% Target Price109.95 Perf Year2.15%
Cash/sh11.29 P/C8.87 EPS next 5Y5.13% ROE28.30% 52W Range93.15 - 107.45 Perf YTD-2.86%
Dividend3.00 P/FCF46.70 EPS past 5Y5.30% ROI18.40% 52W High-6.80% Beta0.52
Dividend %3.00% Quick Ratio2.10 Sales past 5Y3.70% Gross Margin69.30% 52W Low7.51% ATR1.09
Employees126500 Current Ratio2.40 Sales Q/Q-4.10% Oper. Margin28.80% RSI (14)46.30 Volatility1.06% 1.00%
OptionableYes Debt/Eq0.28 EPS Q/Q-6.70% Profit Margin28.10% Rel Volume1.24 Prev Close101.15
ShortableYes LT Debt/Eq0.22 EarningsApr 14 BMO Payout38.10% Avg Volume7.79M Price100.14
Recom2.50 SMA20-0.48% SMA50-0.08% SMA200-1.55% Volume9,655,786 Change-1.00%
May-21-15Reiterated Deutsche Bank Hold $106 → $110
Dec-08-14Reiterated RBC Capital Mkts Outperform $110 → $114
Jul-16-14Reiterated Deutsche Bank Hold $102 → $107
Apr-17-14Reiterated Argus Buy $104 → $116
Apr-16-14Reiterated RBC Capital Mkts Outperform $104 → $106
Jan-10-14Downgrade Barclays Overweight → Equal Weight $99
Jan-07-14Upgrade RBC Capital Mkts Sector Perform → Outperform $88 → $104
Dec-16-13Reiterated Deutsche Bank Hold $93 → $95
Jul-18-13Reiterated Argus Buy $96 → $104
Jul-17-13Reiterated Barclays Overweight $95 → $99
Jul-17-13Downgrade Deutsche Bank Buy → Hold $92 → $93
Apr-18-13Reiterated Argus Buy $80 → $96
Apr-15-13Reiterated Barclays Overweight $85 → $95
Apr-12-13Reiterated Deutsche Bank Buy $82 → $87
Mar-26-13Reiterated UBS Buy $81 → $87
Jan-11-13Reiterated UBS Buy $76 → $78
Jan-04-13Upgrade Deutsche Bank Hold → Buy $75 → $82
Nov-20-12Initiated Stifel Nicolaus Hold
Jul-18-12Reiterated RBC Capital Mkts Sector Perform $65 → $71
Apr-18-12Reiterated UBS Buy $71 → $70
May-30-15 07:35AM  ASCO '15: J&J Antibody Benefits Patients With Hardest-to-Treat Multiple Myeloma at TheStreet
07:30AM  J&J multiple myeloma drug offers hope after others stop working -study
May-29-15 11:51AM  This stock is no longer in the Top 20 most held at CNBC
08:19AM  1 Positive, 1 Negative For Johnson & Johnson Stock
May-28-15 07:32PM  Will Gilead's Hepatitis C Dominance Collapse? at Investopedia
06:53PM  Which Dividend ETFs Provide Steadiest Income? at Investor's Business Daily
06:15PM  J&J accepts offer from Cardinal Health for Cordis unit at Los Angeles Times
09:33AM  Stocks to Watch: Abercrombie & Fitch, Avago Technologies, J&J at The Wall Street Journal
08:50AM  J&J accepts offer from Cardinal Health for Cordis unit
08:26AM  [$$] J&J Accepts Cardinal Health Offer for Heart Business at The Wall Street Journal
08:00AM  Johnson & Johnson Announces Acceptance of Binding Offer From Cardinal Health To Acquire Cordis PR Newswire
12:30AM  FBI Is Investigating Hysterectomy Device Found to Spread Uterine Cancer at The Wall Street Journal
May-27-15 08:14PM  Johnson & Johnson's 3 Most Important Numbers at Investopedia
02:34PM  FBI probing what J&J knew about uterine surgery device - WSJ Reuters
02:30PM  US not thinking about extending nuclear talks
01:54PM  FBI Probes J&J Over Hysterectomy Device at The Wall Street Journal
01:28PM  Utah defends contentious law on contact lens price-fixing
12:57PM  Gilead-GlobeImmune Hepatitis B Drug Fails Trial at Investor's Business Daily
12:17PM  How Law Firms Use Facebook and Other Data to Track Down Medical Victims at Bloomberg
12:17PM  How Law Firms Use Facebook and Other Data to Track Down Medical Victims
12:05PM  3 High-Yield, Low-Risk Dividend Stocks for Extreme Safety at TheStreet
12:02PM  How to Use Options to Profit From Johnson & Johnson's Success at TheStreet
09:30AM  Johnson & Johnson to Participate in the Goldman Sachs 36th Annual Global Healthcare Conference PR Newswire
May-26-15 02:27PM  Jim Cramer -- Here's Why I'm Buy, Buy, Buying J&J and Selling Merck at TheStreet
12:34PM  Cramer: I'm Buying J&J as It Has the Most Upside of Major Pharmas at TheStreet
11:15AM  Abbvie completes $21 billion buyout of Pharmacyclics
09:30AM  The Zacks Analyst Blog Highlights: Johnson & Johnson, AstraZeneca, ACADIA Pharmaceuticals, Actavis and Alkermes - Press Releases
01:48AM  Pharma Trumps All Healthcare Sectors In Executive Compensation at Forbes
May-25-15 08:02AM  Considering the Investment Impact of Baby Boomers Retirement
May-22-15 08:20PM  Johnson & Johnson Seeks to Deliver 10 Blockbusters at Investopedia
04:01PM  The 4 Stocks That Sank the DJIA on Friday at 24/7 Wall St.
05:54AM  Reckitt faces regulatory friction in UK over K-Y acquisition at Financial Times
04:33AM  UK watchdog says Reckitt's K-Y buy could hurt competition Reuters
May-21-15 05:03PM  Hedge Funds Keep Betting Big On Health Care at Forbes
04:58PM  JOHNSON & JOHNSON Files SEC form 8-K, Change in Directors or Principal Officers
04:17PM  J&J Pays Millions to Settle Billion-Dollar Risperdal Case at Bloomberg
03:50PM  J&J (JNJ) to File for More than 10 New Products by 2019 - Analyst Blog
12:38PM  Stocks across all generations
12:06PM  Can This J&J Drug Reshape Schizophrenia Treatment? at Investopedia
11:14AM  S&P 500 Index Futures Trading Higher
11:01AM  Johnson & Johnson meets investors
10:44AM  Johnson & Johnson: Here's Where the Growth Will Come From at
09:30AM  No, Pharmascolds Are Not Worse Than The Pervasive Conflicts Of Interest They Criticize at Forbes
08:49AM  Raymond James: Johnson & Johnson Has 'Innovation'
08:47AM  3 Big Pharmaceutical Stocks to Buy Right Now at TheStreet
08:27AM  What Does The Johnson & Johnson/Achillion Deal Mean For HCV Competitors?
06:20AM  Apple or Microsoft? How to Build a One-Stock Portfolio at TheStreet
May-20-15 03:59PM  Johnson & Johnson expects lucrative return on drug pipeline
02:54PM  J&J to submit at least 10 new drugs for approval by 2019 Reuters
02:49PM  Johnson & Johnson Plans for 10 New Drugs -- Is It Time to Own the Stock? at TheStreet
02:17PM  Johnson & Johnson's $10 Billion Plan for 10 New Drugs by 2019 at TheStreet
02:10PM  Achillion and Johnson & Johnson in $1.1B HCV Tie-Up - Analyst Blog
01:55PM  How biotechs are affecting J&J's business
01:52PM  Achillion Dives As J&J Hep C Deal Chills Buyout Buzz at Investor's Business Daily
12:27PM  Johnson & Johnson Announces it Will File for Ten New Drugs by 2019 at TheStreet
11:44AM  UPDATE 1-Achillion partners with J&J to develop hep C drugs (May 19)
11:38AM  Achillion sinks after partnering with Johnson & Johnson
11:37AM  How Do You Stop Cyber Thieves From Stealing Your Health Data? at TheStreet
10:54AM  Johnson & Johnson's big plans
10:48AM  Johnson & Johnson Has Momentum in Place for a Rally Back to Highs at TheStreet
10:40AM  China Diabetes Management Devices Market Growth to be Driven by Rise in Sedentary Lifestyle and Life Expectancy and Patient Compliant Technologies Especially for Insulin Pump and CGM PR Newswire
09:55AM  Can Another 10 Blockbuster Drugs Really Come From Johnson & Johnson in 5 Years? at 24/7 Wall St.
09:46AM  Gilead Sciences: Little Risk From Achillion's Hep-C Partnership With J&J at
09:20AM  J&J says will submit 10 medicines to regulators by 2019 Reuters
09:11AM  Will Johnson & Johnson (JNJ) Stock be Helped by New Drug Lineup Plan? at TheStreet
08:54AM  JMP Says Stepping To The Sidelines On Achillion
08:17AM  J&J Expects to File at Least 10 New Drugs at The Wall Street Journal
08:12AM  JNJ CEO: Always on the hunt for new platforms
08:08AM  JNJ's 'balance approach' accounts for success: CEO
08:05AM  Driving innovation in pharma: JNJ CEO
07:54AM  Early movers: LOW, JNJ, YHOO, HRL, NOC & more at CNBC
07:49AM  J&J: 10 new drugs by 2019, each with $1B potential at CNBC
07:36AM  J&J Plans Blockbuster Lineup to Revive Momentum in Drug Sales at Bloomberg
07:30AM  Johnson & Johnson Pharmaceutical Segment to Continue Driving Above-Industry Growth with Plans to File More than 10 New Products by 2019, Each with Potential to Exceed $1 Billion in Revenue PR Newswire
07:30AM  JNJ expects 10 new drug filings by 2019
May-19-15 05:44PM  Johnson & Johnson to Invest in Achillion at The Wall Street Journal
04:47PM  Houston, Johnson & Johnson May Have a Problem at Investopedia
04:29PM  Achillion partners with J&J to develop hep C drugs
12:57PM  IBM Watson Unit Targets Online Travel, Shopping Apps at Investor's Business Daily
09:17AM  Pharmalot Pharmalittle Good Morning: We're Catching Up on Endo, J&J, Merck and More . . . at The Wall Street Journal
09:13AM  FDA Grants Priority to J&J Schizophrenia Drug at The Wall Street Journal
08:17AM  Johnson & Johnson Headed Even Higher After Big-Volume Lift at TheStreet
07:00AM  Ultimate Stock-Pickers Top 10 High-Conviction and New-Money Purchases at Morningstar
May-18-15 04:21PM  Healthcare Winners and Losers: May 18, 2015
04:01PM  The 4 Stocks That Lifted the DJIA on Monday at 24/7 Wall St.
10:49AM  Why Stores Cant Sell You Cheaper Contact Lenses
10:34AM  Dow hits record; stocks try for gains despite rising yields, Greece concerns at CNBC
08:03AM  Is the Stock Market Due for a Correction?
07:22AM  Urban Outfitters, Target, Wal-Mart Report Earnings This Week With Retail Stocks in the Spotlight at TheStreet
May-15-15 05:15PM  Biotech movers: JNJ & BLUE
03:07PM  The FDA's Authority Challenged By Mallinckrodt
11:06AM  U.S. FDA warns on newer class of type 2 diabetes drugs Reuters
10:58AM  These Charts Explain Why Johnson & Johnson Should Be Approached Tactically
10:56AM  Apple Inc.( AAPL), The Coca-Cola Co (KO): Billionaire Ray Dalios Top Picks at Insider Monkey
May-14-15 11:58PM  [$$] Can FDA Reclassify Generic Drugs? at The Wall Street Journal
10:52PM  Can FDA Reclassify Generic Drugs? at The Wall Street Journal
06:27PM  Galapagos Receives a Rousing Welcome on Its First Day of Trading at TheStreet
03:57PM  IBM Is Paving the Way for Watson Health: Acquisitions and Deals
03:55PM  US court halts contentious law on contact lens price-fixing
01:00PM  Key Dalio and Bridgewater Position Changes: Alcoa, Apple, CenturyLink, Cisco, Gilead, Emerging Markets at 24/7 Wall St.
Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the health care field worldwide. It operates in three segments: Consumer, Pharmaceutical, and Medical Devices. The Consumer segment offers baby care products under the JOHNSON'S brand name; oral care products under the LISTERINE brand name; skin care products under the AVEENO, CLEAN & CLEAR, DABAO, JOHNSON'S Adult, LE PETITE MARSEILLAIS, LUBRIDERM, NEUTROGENA, and RoC brand names; women's health products, such as sanitary pads under the STAYFREE and CAREFREE, and o.b. tampon brand names; wound care products, including adhesive bandages and first aid products under the BAND-AID and NEOSPORIN brand names; and nutritional products comprising no calorie sweetener under the SPLENDA brand name. This segment also offers over-the-counter medicines, including acetaminophen products under the TYLENOL brand name; cold, flu, and allergy products under the SUDAFED brand name; allergy products under the BENADRYL and ZYRTEC brand names; ibuprofen products under the MOTRIN IB brand name; and heartburn products under the PEPCID brand name. The Pharmaceutical segment provides various products in the areas of immunology, infectious diseases, neuroscience, oncology, and cardiovascular and metabolic diseases. The Medical Devices segment offers orthopaedic, and trauma and neurological products; general surgery, and biosurgical and energy products; products to treat cardiovascular disease; infection prevention products; diagnostics products; blood glucose monitoring and insulin delivery products; and disposable contact lenses. The company distributes its products to general public, retail outlets and distributors, wholesalers, hospitals, and health care professionals for prescription use in the professional fields by physicians, nurses, hospitals, and clinics. Johnson & Johnson was founded in 1885 and is based in New Brunswick, New Jersey.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Stoffels PaulusChief Scientific OfficerApr 28Option Exercise64.43228,68314,733,404281,723Apr 30 04:56 PM
Stoffels PaulusChief Scientific OfficerApr 28Sale100.73187,25018,862,14294,473Apr 30 04:56 PM
Fasolo PeterVP, Global Human ResourcesMar 05Option Exercise65.37115,3077,537,619147,895Mar 09 05:14 PM
Fasolo PeterVP, Global Human ResourcesMar 05Sale102.40115,30711,807,86332,588Mar 09 05:14 PM
Stoffels PaulusChief Scientific OfficerFeb 09Option Exercise0.0029,073064,647Feb 11 08:16 PM
Caruso Dominic JVP, Finance; CFOFeb 09Option Exercise0.0031,5370101,324Feb 11 08:16 PM
Fasolo PeterVP, Global Human ResourcesFeb 09Option Exercise0.0020,935042,109Feb 11 08:16 PM
Gorsky AlexChairman, CEOFeb 09Option Exercise0.0042,1120130,173Feb 11 08:17 PM
COSGROVE STEPHEN JCorporate ControllerJan 16Option Exercise0.0011,1080101,402Jan 21 05:48 PM
Ullmann Michael HVP, General CounselJan 16Option Exercise0.008,949075,628Jan 21 05:48 PM
Caruso Dominic JVP, Finance; CFOJan 16Option Exercise0.0012,615074,216Jan 21 05:48 PM
Gorsky AlexChairman, CEOJan 16Option Exercise0.0016,845094,425Jan 21 05:48 PM
Stoffels PaulusChief Scientific OfficerJan 16Option Exercise0.0011,629039,539Jan 21 05:48 PM
Fasolo PeterVP, Global Human ResourcesJan 16Option Exercise0.008,374024,336Jan 21 05:48 PM
PETERSON SANDRA EGroup Worldwide ChairmanDec 17Option Exercise0.0021,689031,210Dec 19 04:37 PM
JOHNSON & JOHNSON10% OwnerNov 12Buy18.0040,000720,0003,077,005Nov 12 03:06 PM
COSGROVE STEPHEN JCorporate ControllerNov 05Option Exercise66.182,490164,78892,784Nov 07 04:49 PM
COSGROVE STEPHEN JCorporate ControllerNov 05Sale108.552,490270,29390,294Nov 07 04:49 PM
CULLEN JAMESDirectorSep 10Sale104.122,446254,6721,489Sep 11 02:19 PM
Caruso Dominic JVP, Finance; CFOAug 21Option Exercise66.1830,0001,985,40091,600Aug 25 04:35 PM
Caruso Dominic JVP, Finance; CFOAug 21Sale104.3030,0003,129,06961,600Aug 25 04:35 PM